Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
131
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen

Hung-Chin Tsai1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan;3 Department of Parasitology, Kaohsiung Medical University, Kaohsiung, Taiwan;4 Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan;5 Shu-Zen Junior College of Medicine and Management, Kaohsiung, TaiwanCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5441-4386View further author information
ORCID Icon,
I-Tzu Chen1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, TaiwanView further author information
,
Hui-Min Chang6 Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;7 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan;8 Department of Pharmacy and Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung, TaiwanView further author information
,
Susan Shin-Jung Lee1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0001-5162-2414View further author information
ORCID Icon &
Yao-Shen Chen1 Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanView further author information
Pages 3857-3869 | Published online: 20 Jul 2022

Figures & data

Table 1 Demographic Data of the 107 HIV-1-Infected Patients with NNRTI-Based STR Treatment Failure

Table 2 Demographic, Treatment and Resistance Differences Between the 29 Patients Who Failed to the Initial STR and 78 Patients with Virological Failure After Switching to STRs in Univariate Analysis

Table 3 Risk Factors Associated with Doravirine Resistance in Univariate Analysis

Figure 1 Rates of mutations associated with resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. Overall, 88% of the patients had mutations associated with drug resistance to any of the four classes of antiretroviral drugs, including 88% with resistance to NNRTIs, 76% to NRTIs, 5% to PIs and 2% to INSTIs.

Abbreviations: STR, single-tablet regimen; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Figure 1 Rates of mutations associated with resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. Overall, 88% of the patients had mutations associated with drug resistance to any of the four classes of antiretroviral drugs, including 88% with resistance to NNRTIs, 76% to NRTIs, 5% to PIs and 2% to INSTIs.

Figure 2 The prevalence of mutations associated with drug resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. The most common mutations associated with resistance to NRTIs were M184V (57.9%) and K65R (20.6%); for NNRTIs K103N (35.5%), V179D (20.6%) and L100I (15%); for PIs L33F (1.9%), K20T (1.9%) and V32I (1.9%), and for INSTIs G148H (0.9%) and G140S (0.9%).

Abbreviations: STR, single-tablet regimen; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Figure 2 The prevalence of mutations associated with drug resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. The most common mutations associated with resistance to NRTIs were M184V (57.9%) and K65R (20.6%); for NNRTIs K103N (35.5%), V179D (20.6%) and L100I (15%); for PIs L33F (1.9%), K20T (1.9%) and V32I (1.9%), and for INSTIs G148H (0.9%) and G140S (0.9%).

Figure 3 Differences in prevalence of mutation point between 29 patients who failed to the initial STRs and 78 patients with failure after switching to STRs.

Abbreviations: STR, single-tablet regimen; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Figure 3 Differences in prevalence of mutation point between 29 patients who failed to the initial STRs and 78 patients with failure after switching to STRs.

Figure 4 The prevalence of doravirine resistance-associated mutations are shown according to the IAS-USA 2019 HIV drug resistance-associated mutation list. There were no statistically significant differences in the percentage of specific doravirine resistance-associated mutations between the 29 patients who failed to the initial STRs and 78 treatment failures after switching to STRs.

Figure 4 The prevalence of doravirine resistance-associated mutations are shown according to the IAS-USA 2019 HIV drug resistance-associated mutation list. There were no statistically significant differences in the percentage of specific doravirine resistance-associated mutations between the 29 patients who failed to the initial STRs and 78 treatment failures after switching to STRs.

Figure 5 Prevalence rates of resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. Overall, 88% of the patients had drug resistance to any of the four classes of antiretroviral drugs, including 86% who had resistance to NNRTIs, 76% to NRTIs, 3% to PIs and 2% to INSTIs.

Abbreviations: STR, single-tablet regimen; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Figure 5 Prevalence rates of resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients with HIV-1 infection and virological failure to STRs. Overall, 88% of the patients had drug resistance to any of the four classes of antiretroviral drugs, including 86% who had resistance to NNRTIs, 76% to NRTIs, 3% to PIs and 2% to INSTIs.

Figure 6 The prevalence of drug resistance to NRTIs, NNRTIs, PIs and INSTIs among the 107 enrolled patients with HIV-1 infection and virological failure stratified by different NNRTI-based STRs. The figure shows that a total of 28% of 107 patients resistance to tenofovir (TDF), 4% to zidovudine (AZT) and 64% to doravirine.

Abbreviations: STR, single-tablet regimen; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Figure 6 The prevalence of drug resistance to NRTIs, NNRTIs, PIs and INSTIs among the 107 enrolled patients with HIV-1 infection and virological failure stratified by different NNRTI-based STRs. The figure shows that a total of 28% of 107 patients resistance to tenofovir (TDF), 4% to zidovudine (AZT) and 64% to doravirine.

Table 4 Risk Factors Associated with the K65R Mutation in Univariate Analysis

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.